iCAD To Host Third Quarter and Nine Months 2009 Financial Results Conference Call on Thursday, October 29, 2009

• Press Release
• Source: iCAD, Inc.
• On 9:00 am EDT, Monday October 5, 2009

NASHUA, N.H.--(BUSINESS WIRE)--iCAD, Inc. (NASDAQ: ICAD - News), an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, today announced that the Company will release financial results for the third quarter and nine months ended September 30, 2009, following the close of the market on Wednesday, October 28, 2009.

Related Quotes

Symbol	Price	Change
ICAD	1.51	-0.03

{"s" : "icad","k" : "c10,l10,p20,t10","o" : "","j" : ""}

Ken Ferry, President and Chief Executive Officer, and Darlene Deptula-Hicks, Executive Vice President and Chief Financial Officer, will host a conference call for investors beginning at 10:00 a.m. Eastern Time on Thursday, October 29, 2009 to discuss third quarter and nine months 2009 financial results and to answer questions.

Shareholders and other interested parties may participate in the conference call by dialing 866-510-0712 (domestic) or 617-597-5380 (international) and entering passcode 16114889 a few minutes before 10:00 a.m. ET on Thursday, October 29, 2009. The call will also be broadcast live on the Internet at www.streetevents.com, www.fulldisclosure.com and www.icadmed.com.

A replay of the conference call will be accessible two hours after its completion through November 5, 2009 by dialing 888-286-8010 (domestic) or 617-801-6888 (international) and entering passcode 58984549. The call will also be archived for 90 days at www.streetevents.com, www.fulldisclosure.com and www.icadmed.com.

About iCAD, Inc.

iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography (DR) and computed radiography (CR)), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT). Since receiving FDA approval for the Company’s first breast cancer detection product in 2002, over 3,200 iCAD systems have been placed in healthcare practices worldwide. iCAD’s solutions aid in the early detection of the most prevalent cancers including breast, prostate and in the future, colon and lung cancer. For more information, call (877) iCADnow or visit www.icadmed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:

Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “anticipate,” “likely,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.

For iCAD
Darlene Deptula-Hicks, 603-882-5200 x7944
ddeptula@icadmed.com
or
For Investor Relations
Lippert/Heilshorn & Associates
Anne Marie Fields, 212-838-3777 x6604
afields@lhai.com
or
For Public Relations
MS&L
Liza Heapes, 617-369-8787
liza.heapes@mslworldwide.com